CASE REPORT FORM

Version 1.0 (12-May-2022)

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given Intramuscularly in Participants Aged 18 to 60 Years

QUADRIFLU

CLINICAL	TRIAL	SITE/UN	IT:

HOSPITAL BANGKOK (A) ¹

HOSPITAL CHIANG MAI (B)²

PRINCIPAL INVESTIGATOR:

Dr. Pl. Principal

Subject Initials:			
Subject ID:			

tudy Code:	Subject ID:			Subject initials:				
ELIGIBILITY AND	CREENING							
Screening ID			site code fo	ollowed by 3 digits visit	randomi	sation n	umber)	
Inclusion Criteria					Yes	I	No* ²	
1 Is the subject a hea	althy adult aged betwe	een 18 and	60 years	s?				
2 Has the subject wil	ingly given written inf	ormed cor	sent?					
3 Able and willing to	comply with study req	luirements	and follo	w-up?]
*If any inclusion criteria	are ticked NO then the	e patient is	not eligi	ble for the study.				
Exclusion Criteria					Yes*	1	No ²	_
1 If female, does the	subject is pregnant (b	based on-s	ite urine	test) or lactating?				
2 Have a vaccination	schedule within 3 we	eks of stud	dy duratio	on?				
3 Taken any vaccine	in the past 4 weeks?]
4 Taken influenza va	ccination in the past 6	6 months?		[
5 Had history of influe	Had history of influenza infection in the past 6 months?							
6 example: a) cancer dependent diabeter	Has a serious disease in the opinion of the investigator including, for example: a) cancer, b) heart disease, c) autoimmune disease, d) insulin dependent diabetes mellitus, e) chronic pulmonary disease, f) acute or progressive hepatic disease, g) acute or progressive renal disease?]
*If any exclusion criteria	are ticked YES then t	the patient	is not eli	gible for the study.				
Is subject eligible?	Yes ¹]	No (scre	een failure) ²]			
If enrolled						-		
Enrollment date (DD/MMM/YYY)	/			/				
Enrollment time (24h format, HH:MM)								
Subject Initials		(initial of	first, middl	e, last name)				
Subject ID				ollowed by 3 digits treat on number)	ment allo	ocation		
Date of informed consent signed / / / /								
Time of informed consen (24h format, HH:MM)	t signed	:						
Eligibility criteria confirme	ed by							
				/	/			
Interviewer name	Signa	iture	_ L	Date (DD/MM	M/YYYY)	<u> </u>	

Study Code:	Subject ID:		S	Subject initials:		
LABORATORY ANALYS	IS					
Screening ID		(s	ite code foll	owed by 3 digits visit random	isation number)	
Sample collection date (DD/MMM/YYYY)	/		/			
Sample collection time (24h format, HH:MM)	:					
Pregnancy test result (Fem	ale only) P	ositive* 1	Ne	egative ²		
	*Pc	sitive tested	d subject	t is INELIGIBLE		

Done by (staff initials)

Study Code: Subject ID:		Subject initials:		
-------------------------	--	-------------------	--	--

ENROLLMENT (DAY 0)

Enrollment date (DD/MMM/YYYY)								
DEMOGRAPHIC DATA								
Age:		Birth year (YYYY)						
Sex:	Female ¹	Male ²						
Race:	Thai ¹	Asian non-Thai ² Other ³						
MEDICATIONS TAKEN Is the subject currently or previously taking any medication including OTC, vitamins and/or supplements? Yes* 1 *Record <u>all</u> medication on Concomitant Medications page								
VITAL SIGNS								
Height:		cm Weight kg						
Body temperature:	°C							
Pulse rate		bpm						
Blood pressure		/ mmHg						
Respiration rate		breaths per minute						

	System	Result (check that apply)	Abnormal finding / Details
	General	Normal ¹	
1		Abnormal ²	
	Appearance	Not done ³	
	Abdomen	Normal ¹	
2	(includes liver	Abnormal ²	
-	and spleen)	Not done ³	
		Normal ¹	
3	Cardiovascular/	Abnormal ²	
3	Heart	Not done ³	
		Not done ³	
4	Extremities	Abnormal ²	
4	Extremities	Not done ³	
		Normal ¹	
6	Genitourinary	Abnormal ²	
0	Germournary	Not done ³	
	Head, Ears,	Normal ¹	
7	Eyes, Nose and Throat	Abnormal ²	
'		Not done ³	
	moat	Normal ¹	
8	Lymph Nodes	Abnormal ²	
0	Lymph Nodes	Not done ³	
		Normal ¹	
9	Musculoskeletal	Abnormal ²	
0	Massaloskeletai	Not done ³	
		Normal ¹	
10	Neck/Thyroid	Abnormal ²	
		Not done ³	
		Normal ¹	
11	Neurological	Abnormal ²	
	5	Not done ³	
	Bulmonon/	Normal ¹	
12	Pulmonary/	Abnormal ²	
	Chest	Not done ³	
		Normal ¹	
13	Skin	Abnormal ²	
		Not done ³	

Study Code: Subject ID:		Subject initials:				
-------------------------	--	-------------------	--	--	--	--

LABORATORY ANALYSIS	
Sample collection date (DD/MMM/YYYY)	
Sample collection time (24h format, HH:MM)	
A/H1N1 Antibody Titer	IU/mL
A/H3N2 Antibody Titer	IU/mL
B/Yamagata-lineage Antibody Titer	IU/mL
B/Victoria-lineage Antibody Titer	IU/mL
	Done by (staff initials)
VACCINATION ADMINISTRATION	
Vaccination date (DD/MMM/YYYY)	
Vaccination time	

Vaccination time (24h format, HH:MM)		
Vaccination arm	Right ¹	Left ²
		Done by (staff initials)

Study Codo:	Subject ID:		Subiect initials:		
Study Code:	Subject ID.		Subject millais.		

CONCOMITANT MEDICATION			(if extra page is no	Page number (if extra page is needed)			Last page? Yes ¹ No ²				
Is the	Is the subject taking/has taken any other medication since last visit?										
Drug name			Start date / time (DD/MMM/YYYY) / (24h, HH:MM)	End date / time (DD/MMM/YYYY) / (24h, HH:MM)	Dose	Unit	Route	Frequency	Reason (put AE/SAE number if associated with AE/SAE)		
									AE #:		
									SAE #:		
			Unknown	On going							
Unit Cap (Capsule dosing unit); g (Gram); IU (International Unit); mg (Milligram); mL (Milliliter); Puff (Puff dosing unit); Tab (Tablet dosing unit); ug (Microgram); OTR (Other)											
Key Route 1 = Intralesional; 2 = Intramuscular; 3 = Intraocular; 4 = Intravenous; 5 = Nasal; 6 = Oral; 7 = Rectal; 8 = Respiratory (inhalation); 9 = Subcutaneous; 10 = Topical; 11 = Transdermal; 12						ermal; 12 = Other					
	Frequency	BID (T	wice per day); PRN (As needed); QD (Daily); QID (4 times per day); QM (Every Month); QOD (Every oth	ner day); TID (3 times per day); UNK (Unkno	own)			